Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (2012) Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 67(12):2793–2803
Article
CAS
Google Scholar
Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, De Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L (2016) A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60(7):4159–4169
Article
Google Scholar
Gutierrez-Gutiérrez B, Rodríguez-Baño J (2019) Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. Clin Microbiol Infect 25(8):932–942
Article
Google Scholar
Harris PN, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E (2018) Effect of piperacillin–tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 320(10):984–994
Article
CAS
Google Scholar
Muhammed M, Flokas ME, Detsis M, Alevizakos M, Mylonakis E (2017) Comparison between carbapenems and β-lactam/β-lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. In: Open Forum Infectious Diseases, vol 4, no 2. Oxford University Press
Harris PN, Yin M, Jureen R, Chew J, Ali J, Paynter S, Paterson DL, Tambyah PA (2015) Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrob Resist Infect Control 4(1):14
Article
Google Scholar
Chang HJ, Hsu PC, Yang CC, Kuo AJ, Chia JH, Wu TL, Lee MH (2011) Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case–control study. J Microbiol Immunol Infect 44(2):125–130
Article
Google Scholar
Institute for Medical Research. National Antibiotic Resistance Surveillance Report 2017. Institute for Medical Research, Kuala Lumpur
Ministry of Health Malaysia. National antimicrobial guideline 2019. Ministry of Health Malaysia, Kuala Lumpur
Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE (2015) Carbapenem therapy is associated with improved survival compared with piperacillin–tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 60(9):1319–1325
PubMed
PubMed Central
Google Scholar
Chopra T, Marchaim D, Veltman J, Johnson P, Zhao JJ, Tansek R, Hatahet D, Chaudhry K, Pogue JM, Rahbar H, Chen TY (2012) Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 56(7):3936–3942
Article
CAS
Google Scholar
Wang R, Cosgrove SE, Tschudin-Sutter S, Han JH, Turnbull AE, Hsu AJ, Avdic E, Carroll KC, Tamma PD (2016) Cefepime therapy for cefepime-susceptible extended-spectrum β-lactamase-producing Enterobacteriaceae bacteremia. In: Open forum infectious diseases. May 1, vol 3, no 3, p ofw132. Oxford University Press
Groupa IH (2012) b-Lactam/b-Lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum b-lactamase–producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54(2):167–174
Article
Google Scholar
Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1998) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16(3):128–140
Article
Google Scholar
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801–810
Article
CAS
Google Scholar
Suetens C, Latour K, Kärki T, Ricchizzi E, Kinross P, Moro ML, Jans B, Hopkins S, Hansen S, Lyytikäinen O, Reilly J (2018) Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Eurosurveillance 23(46):1800516
Article
Google Scholar
Monmaturapoj T, Scott J, Smith P, Abutheraa N, Watson MC (2021) A systematic review and narrative synthesis of pharmacist-led education-based antimicrobial stewardship interventions and their effect on antimicrobial use in hospital inpatients. J Hosp Infect 115:93–116
Article
CAS
Google Scholar
Abubakar U, Syed Sulaiman SA, Adesiyun AG (2019) Impact of pharmacist-led antibiotic stewardship interventions on compliance with surgical antibiotic prophylaxis in obstetric and gynecologic surgeries in Nigeria. PLoS ONE 14(3):e0213395
Article
CAS
Google Scholar
Abubakar U, Tangiisuran B (2020) Nationwide survey of pharmacists’ involvement in antimicrobial stewardship programs in Nigerian tertiary hospitals. J Global Antimicrob Resist 21:148–153
Article
Google Scholar
Abubakar U, Muhammad HT, Sulaiman SA, Ramatillah DL, Amir O (2020) Knowledge and self-confidence of antibiotic resistance, appropriate antibiotic therapy, and antibiotic stewardship among pharmacy undergraduate students in three Asian countries. Curr Pharm Teach Learn 12(3):265–273
Article
Google Scholar
Abubakar U, Sha’aban A, Mohammed M, Muhammad HT, Sulaiman SA, Amir O (2021) Knowledge and self-reported confidence in antimicrobial stewardship programme among final year pharmacy undergraduate students in Malaysia and Nigeria. Pharm Educ 21:298–305
Article
Google Scholar
Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC (2016) Empiric piperacillin–tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. PLoS ONE 11(4):e0153696
Article
Google Scholar
Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W (2017) Randomized controlled trial of piperacillin–tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis 17(1):404
Article
Google Scholar
Casqueiro J, Casqueiro J, Alves C (2012) Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 16(Suppl1):S27
PubMed
PubMed Central
Google Scholar